IDEX (IEX) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales grew 1% to $798 million, with organic sales flat and strong free cash flow of $192 million, representing 133% of adjusted net income.

• Adjusted diluted EPS declined 10% to $1.90, while reported net income fell 43% to $119.1 million due to prior-year divestiture gains and higher costs.

• Mott Corporation was acquired for $986 million, rapidly integrated, expanding material science and production capacity, and expected to be accretive to adjusted EPS in 2026.

• Fire & Safety/Diversified Products segment achieved record sales, while Health & Science Technologies saw strong orders but lower sales.

• Operating cash flow was $205 million, down 9% year-over-year.

Financial highlights

• Q3 sales were $798 million, up 1% year-over-year; organic sales flat, M&A contributed 1%.

• Adjusted gross margin rose 40 bps to 44.6%; adjusted EBITDA margin was 26.9%, down 150 bps year-over-year.

• Free cash flow was $192 million, down 7% year-over-year, with a 133% conversion rate of adjusted net income.

• Net income margin dropped to 14.9% from 26.3% year-over-year.

• Adjusted net income for Q3 2024 was $144.1 million.

Outlook and guidance

• Q4 2024 organic revenue growth expected at 3–4%, with adjusted EBITDA margin near 27%.

• Full-year 2024 organic sales expected to decline 1–2%; adjusted EPS guidance is $7.85–$7.90.

• Full-year GAAP diluted EPS guided to $6.65–$6.70, down from previous $6.85–$6.95, reflecting Mott acquisition impacts.

• Free cash flow conversion expected to exceed 100% of adjusted net income.

• Management expects current cash, operations, and available credit to be sufficient for foreseeable needs.